Clinical Trial

Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion.

Name: Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion. — clinical trial record (NCT07766317)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: GT201

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a multicenter, single-arm phase 1/2 clinical trial to evaluate the safety and tolerability of GT201 as a monotherapy or in combination with anti-PD-1 therapy in patients with advanced solid tumors, and to evaluate the efficacy of this therapy.

Trial Details

NCT Number	NCT07766317
Lead Sponsor	Gritbio Medicine, Inc.
Conditions	Advanced Solid Tumors Cancer
Enrollment	63 participants
Start Date	2026-11
Primary Completion	2030-06 (estimated)
Study Completion	2032-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-14